DMIIR · Drugs Made In America Acquisition II Corp. · Debt
$0.07
At close · Oct 21
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“management has determined that these conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.”View the 10-Q filed Aug 14, 2026
Market Cap
$649.42M
Shares
63.70M
Volume · Oct 21
87.57K
Avg daily vol (3M)
24.86K
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current portion of notes payable | 2026-06-30 | USD 450,000 | 10-Q filed 2026-08-14 |
| Short-term borrowings | 2026-06-30 | USD 450,000 | 10-Q filed 2026-08-14 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Key facts
CIK
2040475
CUSIP
G2851K104
13F (30d)
1 filings
1 filers